New Year, New Hurdles: What's in Store for Biosimilars in 2023
Season 5, Episode 13, Dec 18, 2022, 12:00 PM
On this episode, Brian Biehn, senior director of biosimilar commercialization at AmerisourceBergen, explored how the new year may play out for biosimilars, including his predictions or how uptake will be influenced in the adalimumab market and how government policies will impact the competitiveness of the market.
To read more about adalimumab biosimilars, click here.
To read more about ophthalmology biosimilars, click here.
To learn more about the Inflation Reduction Act’s impact on biosimilars, click here.
To read more about the reauthorization of the Biosimilars User Fee Amendment, click here.
To learn more about interchangeability, click here.
To read more about ophthalmology biosimilars, click here.
To learn more about the Inflation Reduction Act’s impact on biosimilars, click here.
To read more about the reauthorization of the Biosimilars User Fee Amendment, click here.
To learn more about interchangeability, click here.